What are therapeutic monoclonal antibodies?
monoclonal antibodies are used in medicine as a form of immunotherapy, a therapy aimed at using the response of the human immune system to treat the disease. More specifically, therapeutic monoclonal antibodies are usually used to treat some form of cancer. However, monoclonal antibody therapy may have potentially serious side effects, including allergic reactions, low blood pressure, fever, nausea and respiratory interests. The antibodies of the immune system are able to recognize and attack various antigens. The targeted form of immunotherapy, therapeutic monoclonal antibodies have generally affinity for a specific antigen or cell type. They are usually used to treat certain types of cancer, including non-Hodgkin's lymphoma and breast cancer. Sometimes they are also used in the treatment of autoimmune disorders, such as heavy Proms systemic lupus erythematosus.
There are two different categories of monoclonal antibodies and medicines that belong to each category work in different waysy. Some therapeutic monoclonal antibodies, such as rituximab, are detected by specific antigens causing diseases in the body and attach to them. In the case of rituximab, the drug is connected to a protein called CD20. This substance is found on all mature B cells in the body - B cells are a type of immune system cell. The patient's immune system is triggered by this process and continues to attack all cells to which therapeutic monoclonal antibodies are connected.
The second category of monoclonal antibodies includes a number of drugs used to treat different types of cancer. Antibodies in this category generally focus on specific proteins that help malignant cells to multiply in the body. Monoclonal these proteins are attached to antibodies and block communication between them and cancer cells. In some cases this means that malignant cells may stop multiplying and in others withE can reduce cancer because they are starved from their blood and nutrients. Drugs in this category include cetuximab, bevacizumab and trastuzumab.
Use of high -degree drugs, such as therapeutic monoclonal antibodies, can offer some degree of protection for cells that do not deal with the disease process and therefore do not focus on the treatment of malignancies. As with all drugs, there are a number of side effects associated with monoclonal antibodies, such as the low number of red blood cells, low blood pressure, irregular heart rhythm, breathing problems and nausea. Monoclonal therapy of antibody is usually administered by intravenous infusion. The side effects that may occur during infusion may be related to the speed and reduction of the speed at which the drug Identified S can help reduce the power of infusion reactions.